Liu, Yutong http://orcid.org/0000-0001-5683-5451
Sperling, Adam S.
Smith, Eric L.
Mooney, David J. http://orcid.org/0000-0001-6299-1194
Article History
Accepted: 29 September 2022
First Online: 14 February 2023
Competing interests
: A.S.S. has consulted for Adaptive Technologies. E.L.S. has had research funded by Bristol Myers Squibb and Sanofi, is on the scientific advisory boards of Bristol Myers Squibb, Sanofi, and Chimeric Therapeutics and the data safety monitoring board of Eureka Therapeutics, has consulted for Chroma Medicine, ImmuneBridge, Secura Bio, Clade Therapeutics, Sana Biotech and Allogene, and holds licensed patents for BCMA and GPRC5D targeted CAR T cells licensed to Bristol Myers Squibb and for GPRC5D targeted antibody therapies licensed through Sanofi. D.J.M. has had research sponsored by Novartis, has consulted for Medicenna, Johnson & Johnson and IVIVA Medical, and has equity in Lyell and Attivare. Y.L. declares no competing interest.